title: Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies.
abstract: The features of graft-versus-host disease (GVHD) were compared between patients who underwent myeloablative conditioning and received a peripheral blood stem cell transplant (PBSCT) from either a haploidentical donor (HID) or a matched sibling donor (MSD) during the same period of time. The HID group included more patients with advanced disease. Both groups received the same GVHD prophylaxis with the addition of antithymoglobulin (ATG) in HID group. Higher cumulative incidences (CI) of acute GVHD grade 2-4 (35·1% vs. 13·9%, P = 0·003), similar CI of grade 3-4 (14·5% vs. 9·8%, P = 0·595), less 3-year CI of extensive chronic GVHD (17·1% vs. 41·5%, P = 0·017) and less severe chronic GVHD (5·8% vs. 21·2%, P = 0·049) occurred in the HID group compared with the MSD group. There was no difference in the sites of the involved organs between these two groups. Higher 3-year CI of non-relapse mortality (24·0% vs. 10·2%, P = 0·014), relapse (39·0% vs. 22·6%, P = 0·032) and inferior disease-free survival (45·7% vs. 78·9%, P = 0·000) were recorded in the HID cohort compared with the MSD group. More HID patients had Karnofsky scores above 90 than those in MSD group (P = 0·016). In conclusion, ATG plays a key role in the unmanipulated HID PBSCT protocol, producing better quality of life in survivors.
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Hong-Hua
authors.initials: HH
authors.lastname: Li
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Fei
authors.initials: F
authors.lastname: Li
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Chun-Ji
authors.initials: CJ
authors.lastname: Gao
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Wen-Rong
authors.initials: WR
authors.lastname: Huang
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Bo
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Dou
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Li-Li
authors.initials: LL
authors.lastname: Wang
authors.affiliation: Hainan Branch of General Hospital of PLA, Department of Hematology, Sanya, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Jing
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Wang
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Wen-Jun
authors.initials: WJ
authors.lastname: Li
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Li
authors.initials: L
authors.lastname: Yu
authors.affiliation: Chinese PLA General Hospital, Hematology Department, Beijing, China.
authors.forename: Dai-Hong
authors.initials: DH
authors.lastname: Liu
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000276:immunology* / Q000473:pathology; D019337:Hematologic Neoplasms / Q000628:therapy*; D006648:Histocompatibility; D006801:Humans; D015994:Incidence; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D011788:Quality of Life; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000379:methods; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum
keywords: graft-versus-host disease; haploidentical; peripheral blood; stem cell transplantation; unmanipulted